Day 2 of the 19th Annual NY GU Cancers Congress is in full swing! Check out onclive.com for all of our coverage of the meeting #oncology #kcsm #RCC #prostatecancer

Great discussion this morning at #EAU26 on health literacy and shared decision making for vulnerable patients with prostate cancer.

Thanks to everyone that joined the session! 💙

#CLEARPC #EU4Health #ProstateCancer #HealthLiteracy

Biotech companies, investors pour billions into mRNA vaccines as research ramps up in cancer and non-communicable diseases - The Cancer Letter After the stunning success of mRNA vaccines during the COVID-19 pandemic, researchers and biotech companies are racing to prove the utility of the technology in an array of non-communicable diseases—i...

Encouraging news in prostate cancer research: pairing next-generation immunotherapy with standard hormone therapy before surgery may help overcome long-standing treatment barriers.

#ProstateCancer #Immunotherapy #CancerResearch #Oncology #TCSC
cancerletter.com/the-cancer-l...

Racial Differences Do Not Affect PSA Response With Lutetium Lu-177 Vipivotide Tetraxetan in mCRPC | OncLive PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC.

PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC, according to data from retrospective cohort study presented during @ascocancer.bsky.social #GU26 #oncology #pcsm #prostatecancer
Read more here: www.onclive.com/view/racial-...

Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.

NCHR President Diana Zuckerman told reporters this panel should include more diversity of opinion than has been seen recently.

Cancer patients deserve rigorous, transparent reviews with solid evidence.

#FDA #CancerResearch #BreastCancer #ProstateCancer

www.biospace.com/fda/two-astr...

Thank you to Maha H. Hussain, MD, FACP, FASCO, of @nufeinbergmss.bsky.social for presenting on treatment intensification in mHSPC! Stay tuned to onclive.com for all of our coverage of the 19th Annual NY GU Cancers Congress! #oncology #pcsm #ProstateCancer

Scan that makes prostate cancer cells glow could reduce the need for biopsies – BioNews Central PSMA PET/CT imaging uses a molecule that highlights aggressive prostate cancer cells as bright spots, helping distinguish cancers that require treatment from low-risk cases to prevent overdiagnosis.

PSMA PET/CT #imaging uses a molecule that highlights aggressive #ProstateCancer cells as bright spots, helping distinguish cancers that require treatment from low-risk cases to prevent #overdiagnosis.
#PSMAPETCT #EAU26

March Issue: Lymph Node Invasion Prediction in #ProstateCancer : A Comparative Machine-Learning Study

https://rdcu.be/e70D3

Dr @alison-tree.bsky.social led the TRAP trial at The Royal Marsden, exploring targeted SBRT, a precise radiotherapy, for men with advanced #ProstateCancer.

The trial looked at whether SBRT could delay chemotherapy and maintain quality of life.

📙 Read more: prostatecanceruk.org/research/res...

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study We present new risk nomograms by PROMISE along with a simple table to prognosticate 3-year, 5-year, and 7-year overall survival in prostate cancer. PROMISE and PPP3 assessments are freely available on...

New #ProstateCancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. www.thelancet.com/journals/lan...

Podcast: Current Insights and Emerging Trends in #MolecularImaging and #Theranostics for #ProstateCancer
www.diagnosticimaging.com/view/reading...
#radiology #RadRes

Dr Jason Efsthathiou, presents PEACE-3 data: Adding Radium-223 to enzalutamide prolongs rPFS (19.4 vs 16.4 mo, HR 0.69) in #mCRPC with bone metastases. Research from Dr Enrique Gallardo.

Read the review and watch the full interview at: ➡️ https://bit.ly/4rNUPUK

#MedEd #OncTwitter #ProstateCancer

Quality of Care and Survival Outcomes Among Patients With Clinically Localized Prostate Cancer in Nigeria Optimal survival outcomes of prostate cancer are best achieved through high-quality care for curable disease. In Nigeria, various barriers may impede the curative treatment of prostate cancer, yet their impact on care and patient outcomes remains ...

Dr. Ernie Kninjing on survival outcomes among patients with #prostatecancer , from Georgia College and State University, Georgia.

Quality of Care and Survival Outcomes Among Patients With Clinically Localized Prostate Cancer in Nigeria...
pmc.ncbi.nlm.nih.gov/articles/PMC...

📍 The CLEAR-PC project will be at #EAU26 in London this weekend!

Join us on Saturday (14 March) for two sessions on prostate cancer, health literacy, and shared decision-making.

Looking forward to connecting at the congress.

#CLEARPC #ProstateCancer #HealthLiteracy #EU4Health

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TRRj7w !

#Oncology #SocialListening #LucidQuest

Dr. Scott Tyldesley of UBC reports on 15-year ASCENDE-RT data: Brachytherapy boost halves PC-specific mortality (8.6% vs 16.4%, P=.007) but shows no OS benefit.

Read more here: ➡️ https://bit.ly/3OGoIaH

#pcsm #prostatecancer #ASCOGU26 #GU26

An intervention mapping approach to the development and evaluation of a community-based prostate cancer early detection programme in Nigeria Interventions are needed to reduce the global disparity in prostate cancer outcomes. Our research aimed to evaluate the acceptability, feasibility and appropriateness of a stakeholder-developed intervention for the early detection of prostate cancer ...

Dr. Faruk Mohammed on #prostatecancer early detection, from Ahmadu Bello University Teaching Hospital, Nigeria.

An intervention mapping approach to the development and evaluation of a community-based prostate cancer early detection...
pmc.ncbi.nlm.nih.gov/articles/PMC...

Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses data from a real-world analysis of androgen pathway receptor triplet regimens in mHSPC that were presented during the 2026 Genitourinary Cancers Symposium. #GU26 #prostatecancer #pcsm

🔷 Findings highlight how advanced imaging may refine prognosis and guide more personalized treatment strategies in prostate cancer.

🔗 Read more: bit.ly/ONCOnews-11M...

#ONCOnews #OncoAlert #OncEd #ProstateCancer #PSMAPET #Oncology #CancerResearch #CancerImaging #PrecisionMedicine #Urology #Cancer

S2E140- Barbie does what? Celebrity phobias and more Barbie does what?  Celebrity phobias, unsafe old toys, exploding balls, What can you not trademark and more... www.empoweryourjourneyaprostateguidebook.com

📣 New Podcast! "S2E140- Barbie does what? Celebrity phobias and more" on @Spreaker #barbie #prostatecancer

Prostate cancer treatment is evolving.

Dendritic cell therapy in Mexico uses your own immune cells to recognize and attack tumor cells, offering a approach to cancer care.

placidway.com/answer-detail/571176/How-Effective-Is-Dendritic-Cell-Therapy-for-Prostate-Cancer-in-Mexico

#ProstateCancer

Scientific Paper published in British Journal of Cancer, titled: Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity. Written by Turnham et al.

Could inhibiting c-FLIP enhance the effectiveness of docetaxel in men with #ProstateCancer?

Exciting new research from Cardiff University, led by Prof Richard Clarkson and Dr Daniel Turnham, has been published in British Journal of Cancer.

Grab a ☕ and read: doi.org/10.1038/s414...

Could Pluvicto Be Utilized for Earlier Treatment of #ProstateCancer?
www.diagnosticimaging.com/shorts/pluvi...
#radiology #RadRes #RadOnc

Trial Tuesday! Dr. Deepak Kilari from Medical College of Wisconsin is now enrolling Alliance for Clinical Trials in Oncology A032302, the ASPIRE trial to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. Learn more at http://bit.ly/AllianceA032302

Happy birthday, Dad!
I miss you.
I love you.
#ProstateCancer #ProstateCancerAwareness #Stage4ProstateCancer #Stage4ProstateCancerAwareness #StageFourProstateCancer #StageFourProstateCancerAwareness #Stage4MetastasizedProstateCancer #StageFourMetastasizedProstateCancer #ProstateExamsSaveLives

Over a decade of abiraterone: the drug that revolutionised advanced prostate cancer care This Prostate Cancer Awareness Month, we’re celebrating over 10 years since abiraterone was first recommended by NICE in England as a treatment for advanced prostate cancer.

At the ICR, we discover more prototype cancer drugs than any other academic institution in the world.

One drug we discovered, abiraterone, has helped to give thousands of men with advanced #ProstateCancer, many more years with their loved ones.

www.icr.ac.uk/about-us/icr...

News From Industry: AMPLITUDE Update
Source: GlobeNewswire
www.globenewswire.com/news-release...

European Commission approves niraparib + abiraterone acetate w/ prednisone/prednisolone & androgen deprivation therapy for patients with BRCA1/2-mutated metastatic hormone-sensitive #ProstateCancer

FDA Approves New Formulation of the #PSMA PET Agent Pylarify
www.diagnosticimaging.com/view/fda-app...
#radiology #RadRes #ProstateCancer

Can Cancer Be a Gift? | CURE A stage 4 prostate cancer survivor shares his story of positivity and gratitude.

Can cancer change how someone sees life?

A stage 4 prostate cancer survivor reflects on resilience, gratitude, and the unexpected lessons that can emerge from the cancer journey.

#CancerSurvivor #ProstateCancer #CancerJourney #TCSC

www.curetoday.com/view/can-can...

Two graphs display survival probabilities over time, stratified by BRS. Graph A shows the ACIS cohort, while graph B shows the ELM-PC-5 cohort. Each graph plots four BRS groups, 0 to 3, with decreasing survival probability as BRS increases. Text@1 shows statistical significance.

The Bellmunt Risk Score stratified #ProstateCancer survival and progression risk in patients with metastatic castration-resistant disease, supporting its utility for baseline prognostication in clinical care.

ja.ma/4b63b2K